NKTR logo

NKTR
Nektar Therapeutics

8,532
Mkt Cap
$1.07B
Volume
705,875.00
52W High
$66.92
52W Low
$6.48
PE Ratio
-6.89
NKTR Fundamentals
Price
$54.70
Prev Close
$51.12
Open
$51.27
50D MA
$58.41
Beta
2.08
Avg. Volume
701,165.58
EPS (Annual)
-$8.68
P/B
12.63
Rev/Employee
$1.61M
Loading...
Loading...
News
all
press releases
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 5.5% - What's Next?
Nektar Therapeutics (NASDAQ:NKTR) Trading Down 5.5% - What's Next...
MarketBeat·10h ago
News Placeholder
More News
News Placeholder
Nektar Therapeutics (NASDAQ:NKTR) Trading Down 5.5% - Here's What Happened
Nektar Therapeutics (NASDAQ:NKTR) Trading Down 5.5% - Should You Sell...
MarketBeat·10h ago
News Placeholder
Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy
Does Nektar Therapeutics (NKTR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·5d ago
News Placeholder
Nektar Therapeutics $NKTR Shares Sold by 22NW LP
22NW LP reduced its holdings in Nektar Therapeutics (NASDAQ:NKTR - Free Report) by 93.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC...
MarketBeat·5d ago
News Placeholder
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire SAN FRANCISCO, Dec...
PR Newswire·7d ago
News Placeholder
Stonepine Capital Management LLC Makes New Investment in Nektar Therapeutics $NKTR
Stonepine Capital Management LLC bought a new stake in shares of Nektar Therapeutics (NASDAQ:NKTR - Free Report) in the second quarter, according to its most recent disclosure with the Securities and...
MarketBeat·8d ago
News Placeholder
Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 64.5% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·12d ago
News Placeholder
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Up - Should You Buy?
Nektar Therapeutics (NASDAQ:NKTR) Shares Gap Up - Here's Why...
MarketBeat·16d ago
News Placeholder
Nektar Therapeutics (NASDAQ:NKTR) Coverage Initiated by Analysts at Citigroup
Citigroup assumed coverage on shares of Nektar Therapeutics in a report on Wednesday. They set a "buy" rating and a $102.00 target price on the stock...
MarketBeat·16d ago
News Placeholder
Howard Robin Sells 2,207 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) CEO Howard Robin sold 2,207 shares of the business's stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an...
MarketBeat·16d ago

Latest NKTR News

View

Advertisement|Remove ads.

Advertisement|Remove ads.